# Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

> **NCT04870164** · PHASE1 · TERMINATED · sponsor: **Molecular Partners AG** · enrollment: 53 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ensovibep
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04870164
- **Lead sponsor:** Molecular Partners AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-18
- **Primary completion:** 2022-01-06
- **Final completion:** 2022-01-06
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Due to hypersensitivity observed in 3 subjects, although no stopping rules were met, the Sponsor decided to halt recruitment for further investigation. After analysis of PK, i.m. administration was not required, and recruitment stopped.
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870164, "Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04870164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*